Apnimed

Apnimed is a late-stage clinical pharmaceutical company focused on the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The company's lead product candidate, AD109 (proposed proprietary name Oxnimbi), is a potentially first-in-class once-daily oral combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a selective norepinephrine reuptake inhibitor), designed to target the neuromuscular root cause of upper airway collapse in people with obstructive sleep apnea (OSA). Oxnimbi has completed two Phase 3 clinical trials (SynAIRgy and LunAIRo) and its NDA is currently under FDA review with a PDUFA target action date of February 28, 2027. OSA is estimated to affect approximately 80 million people in the U.S., many of whom remain untreated, as treatment has historically been limited to devices such as CPAP or invasive surgeries. The company recently completed its IPO, raising gross proceeds of $220.8 million, and secured a $150 million senior credit facility to fund commercial readiness and a potential U.S. launch. Apnimed's common stock trades on the Nasdaq Global Select Market under the ticker APMD. Updated Sep 8, 2026